LUMICKS
PrivateLast Round
Debt
Oct 10, 2024
Total Funding Raised
$120.76M
Company Overview
LUMICKS operates in Healthcare & Life Sciences and is based in Amsterdam. Its latest recorded funding round was a Debt round in October 2024.
LUMICKS is a life sciences tools company that develops innovative instruments for dynamic single-molecule and cell avidity analysis to uncover unique molecular and cellular interactions.
Sector
Healthcare & Life Sciences
Verticals
Biotech Equipment, Drug Discovery, Medical Devices, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
LUMICKS Comparables
Compare LUMICKS with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Impetux Optics | 77% | |
| Nicoya Lifesciences Inc. | 74% | |
| Aresis d.o.o. | 74% |
For institutional investors. Book with your work email.
LUMICKS Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Oct 10, 2024 | ||||
| Series D | Apr 16, 2021 | ||||
| Grant | Oct 1, 2020 | ||||
| Grant | May 12, 2015 | ||||
| Debt | Jan 15, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
LUMICKS Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SoftBank Investment Advisers | Series D |
| Farallon Capital Management | Series D |
| SoftBank Group | Series D |
| Lauxera Capital Partners | Series D |
| Gilde Healthcare | Series D, Series A |
| Irving Investors | Series D |
| European Investment Bank Group | Debt |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 10, 2024
$22M round led by European Investment Bank Group.
- Apr 16, 2021
$93M round led by Farallon Capital Management and Lauxera Capital Partners.
For institutional investors. Book with your work email.
LUMICKS Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about LUMICKS's valuation, stock price, and market status.
Is LUMICKS a public or private company?
LUMICKS is a private company.
What is the current stock price of LUMICKS?
LUMICKS is a private company, so its shares have no public market price. Caplight tracks LUMICKS's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is LUMICKS worth (valuation)?
Valuation information for LUMICKS is not publicly available.
Can I buy LUMICKS stock?
LUMICKS shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was LUMICKS's last funding round?
LUMICKS's most recent funding round was Debt on October 10, 2024.
Who are the main investors in LUMICKS?
Key investors in LUMICKS include Farallon Capital Management, Lauxera Capital Partners, Gilde Healthcare, Netherlands Organization for Scientific Research.
Will LUMICKS IPO soon?
No public IPO plans have been announced for LUMICKS.
How can I track LUMICKS secondary market activity?
Caplight tracks bids, offers, and trades in LUMICKS's shares on secondary markets.